Current vascular pharmacology最新文献

{"title":"Effect of Statins on Postprandial Hypertriglyceridemia: Editorial for Hellenic Postprandial Lipemia Study (HPLS), A Prospective Cohort Trial.","authors":"Debabrata Mukherjee","doi":"10.2174/0115701611452284251103112402","DOIUrl":"https://doi.org/10.2174/0115701611452284251103112402","url":null,"abstract":"","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Review of the Use of Peripheral Vasopressors and Their Implications.","authors":"Arihant Surana, Riya Bhattacharya, Akshat Banga, Kevin Martin","doi":"10.2174/0115701611451845260413164652","DOIUrl":"https://doi.org/10.2174/0115701611451845260413164652","url":null,"abstract":"<p><p>The use of peripheral vasopressors has gained attention as a viable alternative to central venous catheter (CVC) administration in critically ill patients. This review explores the evolving evidence on the safety, efficacy, and clinical considerations of peripheral vasopressor use, particularly in acute hypotensive states. Although central access remains the standard for vasopressor administration, delays in CVC placement may necessitate peripheral access as a temporizing measure. While other forms of venous access, such as Peripherally Inserted Central Catheters (PICCs) provide reliable administration routes, they are classified as central access; this review focuses exclusively on the safety and implications of vasopressor administration via peripheral venous catheters (PVCs). Studies have shown that peripheral vasopressors, when administered with proper protocols, can effectively stabilize patients while avoiding the risks associated with CVCs, such as infections, thrombosis, and pneumothorax. However, complications, particularly extravasation, remain a concern. This review discusses various vasopressor agents, including norepinephrine, epinephrine, and dopamine, highlighting their safety profiles and the importance of catheter size, location, and duration of infusion. Furthermore, the review addresses gaps in current guidelines and the lack of standardized protocols. Given the promising results, further research is needed to establish best practices for peripheral vasopressor use, including optimal dosing, duration, and patient selection. A protocol-driven approach, combined with enhanced monitoring, could potentially reduce complications and improve patient outcomes in critical care settings.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation Management in Hemodialysis Patients with Atrial Fibrillation: A Clinical Dilemma.","authors":"Maria Triantafyllidou, Eleni Stamellou, Stefanos Roumeliotis, Konstantinos Leivaditis, Evangelia Dounousi","doi":"10.2174/0115701611424627251217065105","DOIUrl":"https://doi.org/10.2174/0115701611424627251217065105","url":null,"abstract":"<p><p>Atrial Fibrillation (AF) is the most common cardiac arrhythmia and is increasingly prevalent among patients on haemodialysis (HD). It presents a significant clinical challenge due to the elevated risks of both thromboembolic and bleeding events. Although the shift from Vitamin K Antagonists (VKAs) to Direct Oral Anticoagulants (DOACs) is well established in the general population and in patients with moderate Chronic Kidney Disease (CKD), uncertainty persists in HD patients due to limited evidence. This review synthesizes current evidence on anticoagulation therapy in HD patients with AF, evaluating safety, efficacy, and clinical guidelines to inform evidence-based decision-making. We reviewed current evidence, including randomized controlled trials (RCTs), observational studies, meta-analyses, and systematic reviews, on anticoagulation in HD patients with AF. Relevant articles published up to December 2024 were identified via PubMed, Cochrane Library, and EMBASE. Key clinical guidelines (KDIGO, ESH, ACC/AHA/ACCP/HPS) were also included. Overall, evidence in HD patients remains heterogeneous. Small RCTs evaluating DOACS have methodological limitations and conflicting results. However, meta-analyses and large cohort studies show that VKAs do not significantly reduce ischemic stroke or mortality in this population and may increase haemorrhagic risk; poor time-in-therapeutic range is a recurring problem. In contrast, accumulating evidence increasingly favors DOACs, with signals of lower bleeding and at least comparable stroke prevention. Left atrial appendage occlusion (LAAO) is an emerging option that may reduce stroke risk without long-term anticoagulation. While definitive randomized evidence in HD remains lacking, the current data balance suggests a cautious preference for DOACs over VKAs. Further adequately powered RCTs in HD are needed to solidify these recommendations.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics, Clinical Characteristics, and Barriers to Care in Patients with Dyslipidaemia in the Arabian Gulf Region: The Gulf ACTION Registry.","authors":"Khalid F Alhabib, Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A Batais, Turky H Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A ElToukhy, Naji Kholaif, Abdulhalim J Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Mustafa Al Hinai, Hani Altaradi, Ibrahim Al-Zakwani","doi":"10.2174/0115701611397165260302054720","DOIUrl":"https://doi.org/10.2174/0115701611397165260302054720","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluates dyslipidaemia management in the Arabian Gulf region.</p><p><strong>Methods: </strong>The multicentre, multinational longitudinal Gulf ACTION registry includes adults (≥18 years old) on lipid-lowering therapy (LLT) recruited from outpatient clinics at 14 tertiary care centres and 9 primary care clinics across five Arabian Gulf countries.</p><p><strong>Results: </strong>A total of 2884 patients were enrolled (mean age 58±12 years); 63% were male. The median first follow-up was 7 (6-11) months, and the median second follow-up was 14 (12-23) months. Among the cohort, 52% of patients were very high risk, 21% of whom achieved their LDL-C target; 40% were high risk, 24% achieved their LDL-C target; 2% were moderate risk, 72% achieved their LDL-C target; and 6% were low risk, 78% achieved their LDL-C target. Only 24% of the overall cohort and 30% of the very high-risk group were treated with combination LLT.</p><p><strong>Discussion: </strong>Similar to international data from the SANTORINI and INTERASPIRE studies, our study showed that only one-fourth of the very high-risk group and one-third of the high-risk group achieved their LDL-C targets. Potential reasons include lower use of combination therapy, poor health behaviors, and psychosocial factors. The variability in practice patterns across the Arabian Gulf and even among study sites is a limitation.</p><p><strong>Conclusion: </strong>Very high- and high-risk groups were less likely to achieve their LDL-C target. The low use of combination LLT, unhealthy lifestyle, and social factors in the Gulf region were the main reasons for such poor control. Strategies are needed to achieve current guideline-recommended LDL-C targets.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.","authors":"Audrey Delarue, Nicolas Gendron, Agnès Lillo-Le-Louet, Guillaume Goudot, Stephane Roueff, Helene Lazareth, Eric Thervet, Emmanuel Messas, Tristan Mirault, Lina Khider","doi":"10.2174/0115701611453585260316030913","DOIUrl":"https://doi.org/10.2174/0115701611453585260316030913","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Kidney transplantation is a vital therapeutic option for individuals with end-stage renal disease. Among the various immunosuppressive agents available, everolimus, a selective inhibitor of the mammalian target of rapamycin, is widely used. While previous studies have reported an increased risk of venous thromboembolism (VTE) in heart and lung transplant recipients treated with everolimus, its impact in kidney transplant patients remains less explored. This study aimed to investigate the association between everolimus and VTE in renal transplant recipients.</p><p><strong>Methods: </strong>This study is a retrospective observational analysis combining a single-center case series of kidney transplant recipients and a review of cases retrieved from the French National Pharmacovigilance Database.</p><p><strong>Results: </strong>From February 2017 to February 2022, in our center, 5 VTE occurred in five kidney transplant patients treated with everolimus. Among them, 3 patients had recurrent VTE. The median time between everolimus initiation and VTE onset was 11 months [IQR 3.8-15.0]. Everolimus was discontinued in one patient (20.0%) following the VTE event. From the French pharmacovigilance database, 16 additional cases of VTE associated with everolimus in the context of organ transplantation were identified. Among these, 12 (75.0%) patients were male, with a median age of 63 years [IQR 56.5-69.0]. Transplanted organs included heart (43.8%), lung (18.8%), and kidney (18.8%). Pulmonary embolism was the most common presentation, occurring in 11 (68.8%) patients, while 2 (12.5%) patients had isolated lower-limb DVT. Thrombosis at unusual sites was reported in three cases: one upper-limb DVT, one jugular vein thrombosis, and one right ventricular intracardiac thrombus. The median time to VTE onset after everolimus initiation was 24 months [IQR 7.5-42.0]. Everolimus therapy was continued in 13 (81.2%) patients, with dose reduction in 2 (12.5%) and discontinuation in 3 (18.9%).</p><p><strong>Discussion: </strong>Everolimus may increase the risk of VTE in kidney transplant recipients. This risk appears to be higher in patients with a prior history of VTE before transplantation and during the first year following everolimus initiation.</p><p><strong>Conclusion: </strong>Our findings suggest that everolimus may increase the risk of VTE in kidney transplant recipients. Further studies are needed to confirm this association and to evaluate the benefit-risk profile of everolimus compared with other immunosuppressive therapies in renal transplant patients. Type of Research: Single-center and Pharmacovigilance Retrospective Observational Studies.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Role of Statins in Infective Endocarditis: A Meta-Analysis.","authors":"Nadji Hannachi, Antoine Mariotti, Laurence Camoin-Jau","doi":"10.2174/0115701611419387251202152013","DOIUrl":"https://doi.org/10.2174/0115701611419387251202152013","url":null,"abstract":"<p><strong>Introduction: </strong>Statins exhibit pleiotropic effects with potential benefits in several infectious diseases, but their role in infective endocarditis (IE) remains unclear. We evaluated the impact of statin use on the frequency of IE and on key clinical outcomes in patients with IE, specifically embolic events (EE) and mortality.</p><p><strong>Methods: </strong>We conducted a meta-analysis in which the primary outcome was the frequency of IE among statin users compared with non-users. Secondary outcomes included EE and follow-up mortality (6 months to 1 year).</p><p><strong>Results: </strong>Eleven observational studies, eight retrospective and three prospective, were included, comprising a total of 35,844 patients. The frequency of IE was significantly lower in patients receiving statins compared with non-users (odds ratio (OR): 0.52; 95% confidence interval (CI): 0.34-0.80; P=0.003). Statin-treated IE patients also had fewer EE than non-users (OR: 0.50; 95% CI: 0.26-0.96; P=0.04). Follow-up mortality was significantly reduced in IE patients using statins compared with non-users (hazard ratio (HR): 0.70; 95% CI: 0.61-0.80; P<0.00001).</p><p><strong>Discussion: </strong>Statins exert anti-inflammatory, endothelial-stabilizing, and antithrombotic effects that counteract key pathological mechanisms underlying IE. In this meta-analysis, statin use was associated with a lower frequency of IE, fewer EE, and reduced follow-up mortality.</p><p><strong>Conclusion: </strong>This meta-analysis suggests that statins may offer protective benefits against the incidence of IE and its complications. However, these findings should be interpreted with caution and highlight the need for further research.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioimmunology as a New Branch of Medicine.","authors":"Carlo Caiati, Emilio Jirillo","doi":"10.2174/0115701611454278260305061727","DOIUrl":"https://doi.org/10.2174/0115701611454278260305061727","url":null,"abstract":"","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"e15701611454278"},"PeriodicalIF":2.4,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Obstructive Pulmonary Disease and Cardiovascular Disorders.","authors":"Antonis S Manolis, Antonis A Manolis, Theodora A Manolis, Apostolos Vouliotis","doi":"10.2174/0115701611418539260124113737","DOIUrl":"https://doi.org/10.2174/0115701611418539260124113737","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) remains a significant global public health challenge, plagued by substantial morbidity and mortality worldwide; it is one of the main causes of death worldwide, especially during episodes of severe exacerbation. There is a higher COPD burden noted in regions with high smoking prevalence, air pollution, and faster socioeconomic development. There is also a high number of cardiovascular (CV) comorbidities among these patients, pointing to a need for routine CV screening in such circumstances. These two diseases, COPD and CV disease (CVD), are associated via an intricate and multifactorial interplay characterized by convergent risk factors, systemic inflammation, and interlinked pathophysiological mechanisms, with atherosclerosis being a principal inflammatory process linking these two disorders, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. Importantly, despite the fact that CVD is common in COPD, it remains underdiagnosed and undertreated due to overlapping respiratory and cardiac symptomatology. The latter issue is accentuated in the case of heart failure (HF) and coronary artery disease (CAD), whereby HF atypical symptoms may mimic the clinical picture of COPD exacerbation and CAD presenting with atypical symptomatology such as dyspnea on exertion and/or fatigue, which may point to HF/COPD worsening. Thus, a structured CV assessment and management following exacerbations of COPD is needed in order to identify CAD and/or other new heart disease in these patients and guide appropriate management. These issues are discussed with relevant metaanalyses and key guidelines tabulated, and the involved interrelated mechanisms are pictorially illustrated.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Risks of Electronic Cigarettes: Mechanisms, Evidence, and Research Gaps.","authors":"Pandey Pratima, Anit Kumar Sinha, Basant Kumar","doi":"10.2174/0115701611416438251216071232","DOIUrl":"https://doi.org/10.2174/0115701611416438251216071232","url":null,"abstract":"<p><strong>Introduction: </strong>Electronic cigarettes (ECs), or electronic nicotine delivery systems (ENDS), are increasingly promoted as safer alternatives to conventional cigarettes, especially among younger populations. However, concerns remain regarding their cardiovascular effects.</p><p><strong>Methods: </strong>This review synthesized evidence from PubMed, Embase, and Web of Science databases to examine the association between e-cigarette use and cardiovascular health. Eligible sources included observational studies, experimental research, and systematic reviews evaluating exposure to nicotine and other harmful compounds present in e-cigarettes.</p><p><strong>Results: </strong>Evidence indicates that e-cigarette use exposes individuals to harmful chemicals such as nicotine and carbonyl compounds, which are linked to endothelial dysfunction, arrhythmias, coronary artery disease, and progression of atherosclerosis. While some studies suggest reduced exposure to ecigarettes compared with conventional smoking, measurable adverse cardiovascular outcomes remain significant.</p><p><strong>Discussion: </strong>The findings suggest that although e-cigarettes may serve a role in harm reduction and smoking cessation, their potential to induce cardiovascular risk cannot be overlooked. Current evidence highlights both short-term vascular changes and possible long-term health consequences, though robust longitudinal data remain limited.</p><p><strong>Conclusion: </strong>E-cigarette use is associated with cardiovascular risks despite being marketed as a safer alternative to traditional smoking. There is an urgent need for comprehensive, long-term studies and public health initiatives to clarify these risks and guide appropriate regulatory policies.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia.","authors":"Genovefa D Kolovou, Theodoros Katsikas, Petros Kalogeropoulos, Dimitris Panaretos, Vasiliki Giannakopoulou, Vana Kolovou, Stella Iraklianou, Sotiria Limberi, Vasileios Giannaris, Anna Kounali, Niki Katsiki, Despina Perrea, Katerina Anagnostopoulou, Georgios Goumas, Evangelia Siami, Peggy Kostakou, Dimitri P Mikhailidis, Gerald F Watts, Pablo Pérez-Martínez, Jose Lopez-Miranda, Samia Mora, Børge Nordestgaard, Dennis V Cokkinos, Nikolaos Tentolouris, Helen Bilianou","doi":"10.2174/0115701611390916251104053059","DOIUrl":"https://doi.org/10.2174/0115701611390916251104053059","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Both fasting and postprandial hypertriglyceridemia are associated with atherosclerotic cardiovascular disease (ASCVD). The Hellenic Postprandial Lipemia Study (HPLS, NCT02163044) is the largest prospective cohort trial assessing the effects of statin therapy on postprandial lipemia.</p><p><strong>Methods: </strong>Individuals at high or very high risk for ASCVD were evaluated, and their characteristics were recorded at baseline (Visit 1). At Visit 2 (2-4 weeks after Visit 1) and Visit 3 (3-4 months after Visit 2), serum triglyceride (TG) levels were measured after a 12-hour fast (fTG) as well as 4 hours after the ingestion of a commercially available oral fat tolerance test meal (pTG). After Visit 2, all individuals were treated with a statin.</p><p><strong>Results and discussion: </strong>Among 900 participants, 699 completed all 3 visits, and of these, 209 (29.9%) had an abnormal pTG response. The mean (standard deviation, SD) total- and low-density lipoprotein cholesterol concentrations were 225 (50) and 148 (46) mg/dL at Visit 1, 231 (42) and 156 (40) mg/dL at Visit 2, and 171 (28) and 101 (27) mg/dL at Visit 3. At Visit 2, the mean fTG level was 127 (45) mg/dL and pTG was 188 (73) mg/dL with a mean difference of 58 mg/dL (P<0.001). At Visit 3, the mean fTG concentration was 110 (40) mg/dL, while pTG was 140 (54) mg/dL (mean difference: 29 mg/dL; P<0.001). Fasting glucose levels had no impact on pTG response in statin-treated individuals with abnormal postprandial lipemia.</p><p><strong>Conclusion: </strong>Nearly 30% of individuals at high-/very high-risk for ASCVD had postprandial hypertriglyceridemia. Statin treatment normalized abnormal postprandial lipemia in 75.6% of participants, and decreased pTG concentration even in those with normal fTG levels.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}